Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease

R Reilmann; S Tabrizi; B Leavitt; JC Stout; P Piccini; KE Anderson; A Feigin; M Hayden; M Grozinski-Wolff; E Eyal; S Papapetropoulos

doi:10.1007/s13311-015-0390-6

Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease

R Reilmann, S Tabrizi, B Leavitt, JC Stout, P Piccini, KE Anderson, A Feigin, M Hayden, M Grozinski-Wolff, E Eyal, S Papapetropoulos

Psychology

Research output: Contribution to conference › Poster › peer-review

Original language	English
Pages	246-247
Number of pages	2
DOIs	https://doi.org/10.1007/s13311-015-0390-6
Publication status	Published - Jan 2016
Event	Ninth Annual Huntington Disease Clinical Research Symposium - Grant Hyatt , Tampa Bay, United States of America Duration: 24 Oct 2015 → 24 Oct 2015 Conference number: 9th

Workshop

Workshop	Ninth Annual Huntington Disease Clinical Research Symposium
Country/Territory	United States of America
City	Tampa Bay
Period	24/10/15 → 24/10/15

Access to Document

10.1007/s13311-015-0390-6

Cite this

Reilmann, R., Tabrizi, S., Leavitt, B., Stout, JC., Piccini, P., Anderson, KE., Feigin, A., Hayden, M., Grozinski-Wolff, M., Eyal, E., & Papapetropoulos, S. (2016). Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease. 246-247. Poster session presented at Ninth Annual Huntington Disease Clinical Research Symposium, Tampa Bay, Florida, United States of America. https://doi.org/10.1007/s13311-015-0390-6

Reilmann, R ; Tabrizi, S ; Leavitt, B et al. / Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease. Poster session presented at Ninth Annual Huntington Disease Clinical Research Symposium, Tampa Bay, Florida, United States of America.2 p.

@conference{08ab183e692d475e91c1b5daed27b766,

title = "Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease",

author = "R Reilmann and S Tabrizi and B Leavitt and JC Stout and P Piccini and KE Anderson and A Feigin and M Hayden and M Grozinski-Wolff and E Eyal and S Papapetropoulos",

year = "2016",

month = jan,

doi = "10.1007/s13311-015-0390-6",

language = "English",

pages = "246--247",

note = "Ninth Annual Huntington Disease Clinical Research Symposium ; Conference date: 24-10-2015 Through 24-10-2015",

}

Reilmann, R, Tabrizi, S, Leavitt, B, Stout, JC, Piccini, P, Anderson, KE, Feigin, A, Hayden, M, Grozinski-Wolff, M, Eyal, E & Papapetropoulos, S 2016, 'Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease', Ninth Annual Huntington Disease Clinical Research Symposium, Tampa Bay, United States of America, 24/10/15 - 24/10/15 pp. 246-247. https://doi.org/10.1007/s13311-015-0390-6

Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease. / Reilmann, R; Tabrizi, S; Leavitt, B et al.
2016. 246-247 Poster session presented at Ninth Annual Huntington Disease Clinical Research Symposium, Tampa Bay, Florida, United States of America.

Research output: Contribution to conference › Poster › peer-review

TY - CONF

T1 - Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease

AU - Reilmann, R

AU - Tabrizi, S

AU - Leavitt, B

AU - Stout, JC

AU - Piccini, P

AU - Anderson, KE

AU - Feigin, A

AU - Hayden, M

AU - Grozinski-Wolff, M

AU - Eyal, E

AU - Papapetropoulos, S

N1 - Conference code: 9th

PY - 2016/1

Y1 - 2016/1

U2 - 10.1007/s13311-015-0390-6

DO - 10.1007/s13311-015-0390-6

M3 - Poster

SP - 246

EP - 247

T2 - Ninth Annual Huntington Disease Clinical Research Symposium

Y2 - 24 October 2015 through 24 October 2015

ER -

Reilmann R, Tabrizi S, Leavitt B, Stout JC, Piccini P, Anderson KE et al.. Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease. 2016. Poster session presented at Ninth Annual Huntington Disease Clinical Research Symposium, Tampa Bay, Florida, United States of America. doi: 10.1007/s13311-015-0390-6